

Curriculum Vitae of Professor Giovanni Grandi M.D.



Giovanni Grandi was born in Modena (Italy) on 24th December 1985, now he is 39 years old. He is married with Federica, with two sons, Edoardo (4 years old) and Giorgio (2 year old).

Associate Professor since May 2024 for the University of Modena and Reggio Emilia with clinical activity in Azienda Ospedaliero Universitaria of Modena.

Winner of the International Hungarian **"Egon and Ann Diczfalusy Young Scientist Award 2024"** for his important contribution in the research in Womens Health (Szeged, Hungary, September 2024).

- National Scientific Qualification as Full Professor SSD 06/H1 Gynecology and Obstetrics (from 15/06/2023 to 15/06/2034).
- National Scientific Qualification as Associate Professor SSD 06/H1 Gynecology and Obstetrics (from 9/11/2018 to 9/11/2027).
- Head of the **"Preventive and Hereditary Gynecological Oncology Clinic"**, **"Family Planning Clinic"** and **"Lasertherapy for women"** of the University Hospital of Modena.
- Member of the **"Diagnostic Therapeutic Assistance Clinic (PDTA) for endometrial and cervical cancer treatment"** of the University Hospital of Modena.
- Member of the Board of the Doctorate PhD Program in **Innovative Technologies and Products** for the University of Modena and Reggio Emilia.

Research Grants developed after peer-review

- PI of Swiss National Science Foundation (SNSF), ISV Grant number: IZK0Z3_173945 Approved after peer-review on 11/05/2017, funding of 9,220 CHF. This grant was also recognized by the international database Scopus as an Awarded Grant in the candidate's profile.
- PI grant from the European Society of Contraception for the project "A 3-D Approach to Intrauterine Contraception: is a ball better than a T?" with a grant of 9,500 Euros, approved after peer-review by the Internal Scientific Committee of the Company on 02/14/2019, with approval by the CE AVEN Prot. AOU 0019068/19 of 07/03/2019.
- PI of part II of the study "Evaluation of aspects relating to early menopause following bilateral oophorectomy for risk reduction and evaluation of the effectiveness and safety of a short treatment with hormone replacement therapy on the quality of life, on the incidence of mass loss bone and cardiovascular diseases in women carriers of a genetic mutation that predisposes to breast and/or

ovarian tumors" approved by the CE AVEN (PRACTICE 515/19 OF 9/7/2019). This study is part of a project "QUALITY OF (REPRODUCTIVE) LIFE IN YOUNG WOMEN AT INCREASED RISK FOR HEREDITARY BREAST AND/OR OVARIAN CANCER" funded with the 2018 Finalized Research call for Young Researchers from the Ministry of Health with 208,700 Euros.

- Co-PI of the project "Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial characteristics: a prospective, randomized study" (PI: Prof. Fabio Facchinetti) funded with 415,724.67 Euros for the Endometriosis Research Call of the Ministry of Health, approved by the CE AVEN Protocol AOU 0035151/22 of 05/12/2022. PI of this project from 11/1/2023.
- Co-PI of the winning project of the PRIN 2022 call "PRecocious biOmArkers of Unilateral ureTero-pelvic jUnction obstRuction in childrEn. The PRO-FUTURE project" (PI: Dr. P. Marzuillo) with funding of 250,000 Euros.
- Prof. Grandi is acting as PI of Unit 3 of the research project "Genitourinary Syndrome in breast cancer patients: the common untold unmet need" funded by the Emilia-Romagna Finalized Health Research Program (FIN-RER) 2020 with 142,000 Euros.
- Prof. Grandi was the winner as tutor of the Junior Grant "Development of a vaginal ring for the simultaneous administration.....: CO-RING project" at the Department of Medical and Surgical Sciences Maternal-Child and Adult of UNIMORE, Departmental FAR Call, started on 12/1/2023 by Dr. Martina Arabia.

Patent

Inventor of a patent **"Dispositivo per la somministrazione intravaginale di batteri e loro metaboliti"** for the University of Modena and Reggio Emilia, 2025, number P11016IT00.

Clinical Trials

- Prof. Grandi is PI of the single-center study EPISTOP_2022 "Pilot study to verify the effectiveness of the association of epigallocatechin gallate (EGCG), folic acid and vitamin B12 in preventing the persistence of human papillomavirus (HPV) infection" (ongoing).
- Prof. Grandi is PI of "Multicenter, prospective, open-label, non-comparative clinical study to evaluate the type of menstrual bleeding, tolerability and therapeutic adherence during monophasic hormonal contraceptive treatment with norgestimate + ethinyl estradiol, in Italy", EFFIMIA Study (ongoing).
- Prof. Grandi is Co-PI of PPL 20, a phase II trial for the study of tafoxiparin in gestational hypertension (ongoing).
- 2009-2010: Prof. Grandi was study Coordinator for Modena Center of the International MULTICENTRIC STUDY 91781 BAYER CALM (contraception).
- 2013-2014: Prof. Grandi was Sub-Investigator for the Italian MULTICENTRIC STUDY TEVA "BOLERO" (contraception).

Member of National Expert Groups/Scientific Societies

- Prof. Grandi is a member of the board of the Italian Society of Contraception as a councilor from 2020 to today, a role renewed in 2023. Future President of the Society.
- Prof. Grandi was a member of the Internal Scientific Committee (ISC) of the European Society of Contraception and Reproductive Health with Dr. S. Cameron (UK), Dr. T. Bombas (Portugal), Dr. A. Londero (Italy), Dr. A. Sridhar (USA).
- Prof. Grandi was a past member of the Expert Group on Sexual Medicine and Sex Education of the European Society of Contraception and Reproductive Health (2014-2016).
- Prof. Grandi is a founding member of Womens Health Academy, a credible and highly reliable collaborative network between recognized international experts in women's health with the support of Bayer AG with Prof. V. Abalos (Philippines), Prof. L. Bahamondes (Brazil), Prof. J. Bitzer (Switzerland), Prof. A. Black (Canada), Prof. W. Catherino (USA), Prof. D. Costescu (Canada), Prof. K. Gemzell-Danielsson (Sweden), Prof. O . Heikinheimo (Finland), Dr. A. Kubba (UK), Prof. A. Lopes (Brazil), Prof. R.E. Nappi (Italy), Dr. N. Panay (UK), Prof. T. Römer (Germany), Prof. C. Sales (Brazil) and Prof. S. Singh (Canada) from 08-26-2021 to date.
- Prof. Grandi is a founding member of Gyn Factory Italy, a credible collaborative network between young KOL in Obstetrics and Gynecology in Italy with the support of Gedeon Richter from 12-2023 to date.

Editorial Activity

- Editor in Chief of “**The European Journal of Contraception and Reproductive HealthCare**” since 5/2022. Previously Editor of this international Journal since 2016.
- Associate Editor of “**Minerva Obstetrics and Gynecology**” from 1/2022.
- Prof. Grandi is a Member of the Editorial Board of “**Translational Oncology**” (since 3/2021) and of “**Cancer Treatment and Research Communications**” (since 1/2021).

Work and Education

- Since 5/2024: **Associate Professor** - SSD MED 40-06/H1 Obstetrics and Gynecology - University of Modena and Reggio Emilia – University Hospital of Modena.
- Since 5/2021: **Assistant Professor** - SSD MED 40-06/H1 Obstetrics and Gynecology - University of Modena and Reggio Emilia – University Hospital of Modena.
- Since 7/2019 to 4/2021: **Obstetrician and Gynecologist at AOU of Modena** – University Hospital of Modena (Director: Prof. Fabio Facchinetti).
- Since 1/8/2016 to 31/07/2019 (3 consecutive years): Research Fellow at University of Modena and Reggio Emilia – AOU of Modena – SC of Gynecology and Obstetrics (Tutor: Prof. Fabio Facchinetti).
- 28/6/2016: UNIMORE: Specialization in Gynecology and Obstetrics. Score 110/110 with laude.
- May – October 2015: Research fellowship period at the Department of Clinical Research - University of Bern – Switzerland.
- 2011-2016: UNIMORE - AOU of Modena. Residency in Gynecology and Obstetrics.

- 16-02-2011: Qualification to practice as a Medical Doctor – UNIMORE (Score 270/270).
- 2004-7/2010: UNIMORE Degree in Medicine and Surgery (Score 110/110 cum laude [average grade for curricular exams: 29.36])
- For the academic years 2004-2005, 2006-2007 and 2008-2009 I received the award as one of the best students of the University of Modena and Reggio Emilia.
- 1999-2004: A. Tassoni Scientific High School (Modena). High school diploma in experimental computer science (PNI) and science (Score: 100/100).

Scientific Events

PRESIDENT/SCIENTIFIC SECRETARY FOR 27 NATIONAL/INTERNATIONAL CONGRESSES IN GYNECOLOGY/OBSTETRICS:

- LA TERAPIA ORMONALE NELLA DONNA 2012, 2013 AND 2014-VENEZIA, Italy
- I VENERDÌ SIGO 2012-CONTRACCEZIONE-MODENA, Italy
- WEEK END CLINICO SIDR 2012-INFERTILITA' E CONTRACCEZIONE-MODENA, Italy
- VILLA CESI 2012 AND 2013-MODENA, Italy
- PATOLOGIA VULVARE-XXVII NATIONAL CONGRESS OF SICPCV 2012- VENEZIA, Italy
- GIORNATE GINECOLOGICHE DI CASTROCARO 2009 AND 2011, Italy
- GIORNATE GINECOLOGICHE DI SIRMIONE 2013, Italy
- UROGINECOLOGIA 2013, MODENA, Italy
- BAYER WOMENS HEALTH SUMMIT, BERLIN (Germany) 2019
- ENLARGING HOSPITAL MEETING, MODENA (Italy) 2021
- FOCUS ON LA PATOLOGIA DELL'UTERO, MODENA (Italy) 2021
- 16th ESC Congress, Ghent (Belgium), May 2022
- La scelta contraccettiva nei casi difficili. MODENA (Italy), 11/10/2022
- Endocrinologia dall'adolescenza alla perimenopausa, Rimini (Italy), 6/10/2022
- National EXperts round Tables on subcutaneous LARC, Reggio Emilia (Italy) , 28/11/2022
- National EXperts round Tables on subcutaneous LARC, Mogliano Veneto (TV) (Italy), 20/04/2023
- Donna e aceto balsamico: una lunga storia d'amore. Reggio Emilia (Italy), 1/05/2023
- National Congress of The Italian Society of Contraception (SIC), November 2023, MODENA (Italy)
- 17th ESC Congress, Bilbao (Spain), May 2024
- GynEndo MODENA (Italy), 27-27 September 2025
- Evento educativo sull'impianto sottocutaneo, Bergamo, Palermo, Sassari and Lecco (Italy) (2023-2025).

CERTIFIED PARTICIPATION IN ABOUT 180 NATIONAL AND INTERNATIONAL GYNECOLOGICAL AND OBSTETRICAL CONGRESSES IN THE LAST 15 YEARS, IN 150 AS INVITED SPEAKER/CHAIR.

List of Publications

Updated Indexes:

Total articles on Scopus: 136

H-Index: 28

Total Citations: 2,536

1) Understanding Problematic Bleeding When Using Contraception: Guidance for Clinicians.
Barretta M, **Grandi G**.

Open Access J Contracept. 2025 Oct 14;16:131-145.

2) Contraception today and family planning: a comprehensive review and position statement on the ethical, medical, and social dimensions of modern contraception.

Genazzani AR, Fidecicchi T, Arduini D, Benagiano G, Birkhaeuser M, Schenker J, Strauss JF 3rd, Vasquez-Awad D, Arnal JF, Bahamondes L, Bitzer J, Buchholz T, Brincat M, Celis-González C, Creatsas G, De Melo NR, Douxfils J, Gemzell-Danielsson K, Genazzani AD, Gompel A, **Grandi G**, Heikinheimo O, Hernández-Guzmán L, Kumari S, Lintner MM, Luisi S, Mettler L, Nappi RE, Palacios S, Parazzini F, Petraglia F, Pfleiderer G, Rosano G, Serour GI, Simoncini T, Sitruk-Ware R, Sohail R, Urrutia R, Versace V, Kihara AB.

Gynecol Endocrinol. 2025 Dec;41(1):2543423.

3) Ethics and informed consent in clinical trial integrity: An international, multi-stakeholder consensus statement by Cairo Consensus Group.

Fawzy M, Khan KS, Chien P, Bueno-Cavanillas A, Martín-Díaz M, Zamora J, Raviña AR, Pacey A, Zhang JJ, Khalaf Y, Serour G, Aboulghar M, Sallam H, Sánchez VM, Morris RK, Odibo A, **Grandi G**, Wattar B, Ball E, de Lecuona I, Hooft JV', Geary M, Andrews J, Wasim T, Mahran A, Mignini L, Bedaiwy M, Soliman MY, El-Shalkany A, Jawaid SA, Joshi M, Scott JR, Irfan K, Elsuity MA.

Int J Gynaecol Obstet. 2025 Aug 13.

4) Conservative management of enhanced myometrial vascularity (EMV) after a first trimester miscarriage or termination of pregnancy: a retrospective cohort study.

Bertucci E, Sileo FG, Tramontano AL, Varliero F, Danieli A, **Grandi G**, Alboni C, La Marca A, Savelli L.

Eur J Contracept Reprod Health Care. 2025 Jul 31:1-9.

5) The use of hormonal contraceptives in a cohort of healthy women with BRCA mutations under surveillance in an Italian Family Cancer Clinic.

Grandi G, Sgandurra A, Feliciello L, Pedrini V, Guariglia G, Del Duca N, Toss A, Cortesi L, Aguzzoli L, La Marca A.

Eur J Contracept Reprod Health Care. 2025 Jul 22:1-3.

6) Ulipristal acetate for medical abortion: did we really need to create a 'monster'?

Battipaglia C, Genazzani AD, **Grandi G**.

Eur J Contracept Reprod Health Care. 2025 Aug;30(4):167-169.

- 7) Sequential treatment with relugolix combination therapy in women with symptomatic uterine fibroids that were inadequately managed with 52 mg levonorgestrel intrauterine system: the first report.

Grandi G, Barretta M, La Marca A.

Eur J Contracept Reprod Health Care. 2025 Oct;30(5):278-281.

- 8) Hormonal prolonged-release in oral contraception: how far are we from vaginal pharmacokinetics?

Grandi G.

Eur J Contracept Reprod Health Care. 2025 Jun;30(3):123-124.

- 9) Effects of a Monophasic Hormonal Contraceptive With Norgestimate+Ethinyl Estradiol on Menstrual Bleeding: Protocol and Design of a Multicenter, Prospective, Open-Label, Noncomparative Study in Italy.

Cagnacci A, Grandi G, Capobianco G, Fulghesu AM, Morgante G, Biondelli V, Piccolo E, Casolati E, Mangrella M.

JMIR Res Protoc. 2025 Mar 31;14:e63683.

- 10) The "popcorn" sign: the first early ultrasound sign of serous intra-parenchymal ovarian cancer in BRCA mutation carriers.

Grandi G, Sgandurra A, Cortesi L, Toss A, Dominici M, Grisendi V, Pedrini V, Botticelli L, La Marca A.

Arch Gynecol Obstet. 2025 May;311(5):1461-1465.

- 11) Menopause, Perimenopause, and Migraine: Understanding the Intersections and Implications for Treatment.

Waliszewska-Prosół M, **Grandi G**, Ornello R, Raffaelli B, Straburzyński M, Tana C, Martelletti P. Neurol Ther. 2025 Jun;14(3):665-680.

- 12) Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome.

Sighinolfi G, **Grandi G**, Barbieri E, Venturelli M, Piombino C, Melotti C, Lippi Bruni R, Costantini Cuoghi R, D'Amico R, Lambertini M, Peccatori FA, Tenedini E, Dominici M, Cortesi L, La Marca A, Toss A.

Commun Med (Lond). 2025 Mar 8;5(1):70.

- 13) International multistakeholder consensus statement on post-publication integrity issues in randomized clinical trials by Cairo Consensus Group.

Khan KS, Fawzy M, Chien P, Geary M, Bueno-Cavanillas A, Nunez-Nunez M, Zamora J, Bedaiwy M, Serour G, D'Hooghe T, Pacey A, Andrews J, Scott JR, Ball E, Mahran A, Aboulghar M, Wasim T, Abdelaleem M, Maheshwari A, Odibo A, Sallam H, **Grandi G**, Zhang J, Fernández-Luna JM, Jawid SA, Mignini LE, Khalaf Y.

Int J Gynaecol Obstet. 2025 Jun;169(3):1093-1115.

- 14) The prolonged-release oral formulations: a new era in hormonal contraception technology?

Grandi G, Bettoli V, Bruni V, Gambera A, Nappi RE, Cagnacci A.

Eur J Contracept Reprod Health Care. 2025 Feb;30(1):1-2.

- 15) Comment on: Toward an optimal contraception dosing strategy.

Benagiano G, Genazzani AR, **Grandi G**, Guo SW, Habiba M.

PLoS Comput Biol. 2024 Dec 18;20(12):e1012398.

- 16) The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications.

Barretta M, Vignali M, La Marca A, **Grandi G.**

Expert Opin Drug Metab Toxicol. 2024 Dec 17:1-13.

- 17) Tips and tricks for the management of contraceptive etonogestrel implant in clinical practice: an Expert Opinion.

Grandi G, Feliciello L, Sgandurra A, Pedrini V, Guariglia G, Ferrari V, Del Duca N, La Marca A.

Eur J Contracept Reprod Health Care. 2025 Apr;30(2):78-86.

18) Chemoprevention strategies in hereditary breast and ovarian cancer syndromes.

Barbieri E, Venturelli M, Mastrodomenico L, Piombino C, Ponzoni O, Zaniboni S, Barban S, Razzaboni E, **Grandi G**, Dominici M, Cortesi L, Toss A.
Tumori. 2024 Nov 21;3008916241274721.

19) The use of oral GnRH antagonists to inhibit the LH surge in women undergoing ovarian stimulation for in vitro fertilization.

Grisendi V, **Grandi G**, Capuzzo M, La Marca A.
Expert Rev Clin Pharmacol. 2024 Dec;17(12):1089-1091.

20) Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project.

Gori S, De Rose F, Ferro A, Fabi A, Angiolini C, Azzarello G, Cancian M, Cinquini M, Arecco L, Aristei C, Bernardi D, Biganzoli L, Cariello A, Cortesi L, Cretella E, Criscitiello C, De Giorgi U, Carmen De Santis M, Deledda G, Dessena M, Donati S, Dri A, Ferretti G, Foglietta J, Franceschini D, Franco P, Schirone A, Generali D, Gianni L, Giordani S, **Grandi G**, Cristina Leonardi M, Magno S, Malorni L, Mantoan C, Martorana F, Meattini I, Meduri B, Merlini L, Miglietta F, Modena A, Nicolis F, Palumbo I, Panizza P, Angela Rovera F, Salvini P, Santoro A, Taffurelli M, Toss A, Tralongo P, Turazza M, Valerio M, Verzè M, Vici P, Zamagni C, Curigliano G, Pappagallo G, Zambelli A; Italian Association of Multidisciplinary Oncology Groups (AIGOM).
Cancer Treat Rev. 2024 Dec;131:102832.

21) Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.

Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, Cinieri S, Curigliano G, Del Mastro L, De Placido S, Fabi A, Fortunato L, Generali D, Gennari A, Gori S, **Grandi G**, Guarneri V, Klinger M, Livi L, Marchiò C, Palumbo I, Panizza P, Pravettoni G, Pruneri G, Puglisi F, Sapino A, Tinterri C, Turchetti D, De Laurentiis M.
Cancer Treat Rev. 2024 Nov;130:102815.

22) Response to Daungsupawong and Wiwanitkit's Letter to the Editor.

Guida M, Quercitelli L, De Franciscis P, Fiorenza M, Sgandurra A, La Marca A, **Grandi G**.
Eur J Contracept Reprod Health Care. 2024 Oct;29(5):257.

23) Inhibition ratio (I.R.) and transformation index (T.I.): new indexes to compare the effectiveness and clinical behaviour of modern progestin-only pills (POP).

Grandi G, Barretta M, Feliciello L, Vignali M, La Marca A.
Eur J Contracept Reprod Health Care. 2024 Oct;29(5):189-192.

24) The use of a pill containing ethinylestradiol-norgestimate improves female sexuality despite the decrease in circulating androgens: a pilot study.

Guida M, Quercitelli L, De Franciscis P, Fiorenza M, Sgandurra A, La Marca A, **Grandi G**.
Eur J Contracept Reprod Health Care. 2024 Aug;29(4):160-162.

25) The effect of a flavonoid mixture containing diosmin, hesperidin and troxerutin in women with congestion syndrome associated to pelvic pain: a color Doppler ultrasonography study.

Grandi G, Feliciello L, Iaccheri M, Melotti C, Anceschi F, Facchinetti F.
Minerva Obstet Gynecol. 2024 Jun;76(3):250-256.

26) Perception about benefits and risks related to combined hormonal contraceptives use in women with Lynch syndrome.

Barra F, Perrone U, Ferrero S, Bogliolo S, Ottonello S, Gustavino C, Iasci A, Grandi G, Pulliero A, Centurioni MG, Izzotti A.
Ann Med. 2024 Dec;56(1):2370568.

27) Retraction of peer-reviewed articles, a difficult but crucial choice: our experience from The European Journal of Contraception & Reproductive Health Care.

Roumen F, **Grandi G**, Bitzer J.
Eur J Contracept Reprod Health Care. 2024 Apr 2:1-2.

28) Let's reconsider modern progestin-only pills during isotretinoin and retinoid therapy.

Manfredini M, Di Castri L, **Grandi G**.

Eur J Contracept Reprod Health Care. 2024 Apr;29(2):37-39

29) A new progestin-only pill (POP): the impact of drospirenone-only pill 4 mg 24 + 4 on coagulation markers and bleeding patterns.

Guida M, Quercitelli L, De Franciscis P, Ferrara C, Marietta M, Iaccheri M, Facchinetti F, Capasso F, **Grandi G**.

Eur J Contracept Reprod Health Care. 2023;28(6):308-312.

30) Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications.

Battipaglia C, Feliciello L, Genazzani AD, Facchinetti F, **Grandi G**.

Expert Opin Drug Metab Toxicol. 2023 Nov 9:1-9.

31) Can immunohistochemistry improve the pathological diagnosis of placenta accreta spectrum (PAS) disorders?

Losi L, Botticelli L, Mancini L, Negro R, Hanspeter E, Dematté E, **Grandi G**, Facchinetti F, Veneziano M, Malagoli C, Masini M, Fabbiani L, Rivasi F.

Arch Gynecol Obstet. 2023 Aug 3.

32) Phyto-progestins for the treatment of abnormal uterine bleeding without organic cause in women at high risk for breast cancer and breast cancer survivors: a prospective, pilot study.

Grandi G, Facchinetti F, Melotti C, Sgandurra A.

Gynecol Endocrinol. 2023 Jul 21;39(1):2239936.

33) Postpartum contraception: A matter of guidelines.

Grandi G, Del Savio MC, Tassi A, Facchinetti F.

Int J Gynaecol Obstet. 2024 Jan;164(1):56-65.

34) The impact of epidural analgesia on delivery mode in Robson class 1 women: a retrospective cohort study.

Ambrosetti F, **Grandi G**, Petrella E, Sampogna V, Donno L, Rinaldi L, Ghirardini AM, Facchinetti F.

AJOG Glob Rep. 2023 Apr 5;3(2):100207.

35) Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.

Nebgen DR, Domchek SM, Kotsopoulos J, de Hullu JA, Crosbie EJ, Paramanandam VS, Brood-van Zanten MMA, Norquist BM, Guise T, Rozenberg S, Kurian AW, Pederson HJ, Yuksel N, Michaelson-Cohen R, Bober SL, da Silva Filho AL, Johansen N, Guidozi F, Evans DG, Menon U, Kingsberg SA, Powell CB, **Grandi G**, Marchetti C, Jacobson M, Brennan DJ, Hickey M.

BJOG. 2023 Nov;130(12):1437-1450.

36) The role of combined oral contraceptives containing norgestimate for acne vulgaris treatment: a review.

Grandi G, Guariglia G, Facchinetti F.

Eur J Contracept Reprod Health Care. 2023 Jun;28(3):184-191.

37) The Association of Four Natural Molecules-EGCG, Folic Acid, Vitamin B12, and HA-To Counteract HPV Cervical Lesions: A Case Report.

Grandi G, Botticelli L, Fraia PD, Babalini C, Masini M, Unfer V.

J Pers Med. 2023 Mar 22;13(3):567.

38) The drospirenone (DRSP)-only pill: clinical implications in the daily use.

Kubba A, Gemzell-Danielsson K, Palacios S, Wiegratz I, **Grandi G**, Colli E, Regidor PA.

Eur J Contracept Reprod Health Care. 2023 Feb;28(1):36-43.

39) Drospirenone 4 mg in a 24 + 4 regimen in women with contraindications to oestrogen use for contraception: bleeding patterns according to previous menstrual characteristics.

Grandi G, Del Savio MC, Melotti C, Facchinetti F.

Arch Gynecol Obstet. 2023 Mar;307(3):873-879.

40) Attitudes towards menstruation: what women want? An Italian National Survey.

Bastianelli C, **Grandi G**, Farris M, Brandolino G, Paoni Saccone G, La Barbiera I, Benagiano G.

Eur J Contracept Reprod Health Care. 2023 Feb;28(1):28-35.

- 41) We don't have elements to scare women who use oral contraceptives based on noregestrol or chlormadinone about the risk of meningioma. Let's be careful and honest!

Grandi G, Marani G, Facchinetti F, Bahamondes L.

Eur J Contracept Reprod Health Care. 2022 Oct;27(5):355-356.

- 42) BRCA mutation carriers' perception about benefits and risks associated with combined hormonal contraceptives use.

Grandi G, Monari F, Boggio Sola V, Cortesi L, Toss A, Del Savio MC, Melotti C, Centurioni MG, Gustavino C, Varesco L, Facchinetti F, Barra F.

Eur J Contracept Reprod Health Care. 2022 Dec;27(6):439-444.

- 43) Contraception During Perimenopause: Practical Guidance.

Grandi G, Di Vinci P, Sgandurra A, Feliciello L, Monari F, Facchinetti F.

Int J Womens Health. 2022 Jul 15;14:913-929.

- 44) June 24th, 2022: once a right is obtained, it can no longer be lost!

Kopp Kallner H, **Grandi G**.

Eur J Contracept Reprod Health Care. 2022 Aug;27(4):271.

- 45) It is time to talk about replacement of subdermal implants from the same cut, is it always feasible? The slow process of the "armpit approach".

Grandi G, Feliciello L, Negro G, Sgandurra A, Facchinetti F.

Eur J Obstet Gynecol Reprod Biol. 2022 Jul;274:253-254.

- 46) Confirmation of the safety of combined oral contraceptives containing oestradiol on the risk of venous thromboembolism.

Grandi G, Facchinetti F, Bitzer J.

Eur J Contracept Reprod Health Care. 2022 Apr;27(2):83-84.

- 47) Current and future hormonal contraception in Italy: results from an Italian consensus expert meeting.

DI Carlo C, Abbondanza M, Agnello A, Cavalli G, Driul L, Petriglia M, Tinelli A, Tirelli A, Tusei A, **Grandi G**.

Minerva Obstet Gynecol. 2021 Oct;73(5):614-620.

- 48) The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance.

Grandi G, Fiocchi F, Cortesi L, Toss A, Boselli F, Sammarini M, Sighinolfi G, Facchinetti F.

Menopause. 2021 Nov 1;29(1):63-72.

- 49) Vitamin D and green tea extracts for the treatment of uterine fibroids in late reproductive life: a pilot, prospective, daily-diary based study.

Grandi G, Del Savio MC, Melotti C, Feliciello L, Facchinetti F.

Gynecol Endocrinol. 2022 Jan;38(1):63-67.

- 50) A first trimester prediction model for large for gestational age infants: a preliminary study.

Monari F, Menichini D, Spano' Bascio L, **Grandi G**, Banchelli F, Neri I, D'Amico R, Facchinetti F. BMC Pregnancy Childbirth. 2021 Sep 24;21(1):654.

- 51) The use of different doses levonorgestrel-releasing intrauterine system (LNG-IUS): real-world data from a multicenter Italian study.

Bastianelli C, Farris M, Rosato E, Varliero F, Del Savio MC, Facchinetti F, **Grandi G**.

Eur J Contracept Reprod Health Care. 2022 Feb;27(1):16-22.

- 52) Attitudes of women towards products containing hormones (hormonal contraceptives or hormone therapy): what changes from pre to postmenopause?

Grandi G, Del Savio MC, Boggio Sola V, Monari F, Melotti C, Facchinetti F.

Ann Med. 2021 Dec;53(1):908-915.

- 53) The difficult journey to treatment for women suffering from heavy menstrual bleeding: a multi-national survey.

da Silva Filho AL, Caetano C, Lahav A, **Grandi G**, Lamaita RM.

Eur J Contracept Reprod Health Care. 2021 Oct;26(5):390-398

54) BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study.
Grandi G, Boggio Sola V, Cortesi L, Toss A, Giuliani GA, Del Savio MC, Facchinetti F.
Psychooncology. 2021 Oct;30(10):1711-1719.

55) Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis.
Monari F, **Grandi G**, Guidotti I, Torcetta F, Battista R, Coluccio V, Piombino C, Moscetti L, Neri I, Toss A.

Minerva Obstet Gynecol. 2022 Feb;74(1):107-111.

56) Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
Toss A, Tenedini E, Piombino C, Venturelli M, Marchi I, Gasparini E, Barbieri E, Razzaboni E, Domati F, Caggia F, **Grandi G**, Combi F, Tazzioli G, Dominici M, Tagliafico E, Cortesi L.
Genes (Basel). 2021 Apr 21;12(5):616.

57) The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, Filieri ME, Cottafavi L, Giovanardi F, Madrigali S, Civallero M, Marcheselli L, Marchi I, Domati F, Venturelli M, Barbieri E, **Grandi G**, Tagliafico E, Cortesi L.

Diagnostics (Basel). 2021 Mar 21;11(3):565

58) Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.

Grandi G, Sammarini M, Cortesi L, Toss A, Botticelli L, Varliero F, Sighinolfi G, Barbieri E, Facchinetti F.

Menopause. 2021 Feb 1;28(3):263-270.

59) Potentially preventable antepartum stillbirths in a high-resource setting: a prospective audit-based study.

Po' G, Salerno C, Monari F, **Grandi G**, Facchinetti F; Stillbirth Emilia-Romagna Audit Group.

Eur J Obstet Gynecol Reprod Biol. 2021 Mar;258:228-234.

60) The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism.

Grandi G, Del Savio MC, Facchinetti F.

Expert Rev Clin Pharmacol. 2021 Feb;14(2):211-224.

61) Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?

Grandi G, Perrone AM, Perrone A, Mandato VD, Commerci G, Sammarini M, Merisio C, Amadori A, Stefanetti M, Martinello R, Facchinetti F, De Iaco P; Brca Emilia-Romagna Gyneco-Oncological (BERGO) Collaborative Group.

Maturitas. 2021 Jan;143:59-64.

62) Contemporary prescriptions pattern of different dose levonorgestrel-releasing intrauterine systems in an Italian service for family planning.

Grandi G, De Fata R, Varliero F, Del Savio MC, Facchinetti F.

Gynecol Endocrinol. 2020 Dec;36(12):1086-1089.

63) Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA.

Piombino C, Cortesi L, Lambertini M, Punie K, **Grandi G**, Toss A.

J Oncol. 2020 Jul 14;2020:6384190.

64) Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?

Grandi G, Caroli M, Cortesi L, Toss A, Tazzioli G, Facchinetti F.

Expert Opin Drug Saf. 2020 Aug;19(8):1025-1030.

65) The impact of COVID-19 lockdown on admission to gynecological emergency departments: Results from a multicenter Italian study.

Grandi G, Del Savio MC, Caroli M, Capobianco G, Dessole F, Tupponi G, Petrillo M, Succu C, Paoletti AM, Facchinetti F.

Int J Gynaecol Obstet. 2020 Oct;151(1):39-42.

66) Breast cancer screening of mutation carriers in the era of COVID-19 pandemic.

Toss A, Lambertini M, Punie K, **Grandi G**, Cortesi L.

Int J Cancer. 2020 Dec 15;147(12):3574-3575.

67) Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception.

Chiara Del Savio M, De Fata R, Facchinetti F, **Grandi G**.

Expert Rev Clin Pharmacol. 2020 Jul;13(7):685-694.

68) The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study.

Grandi G, Del Savio MC, Sammarini M, Cortesi L, Toss A, Piombino C, Facchinetti F.

Eur J Cancer Prev. 2020 Jul;29(4):350-356.

69) The gendered impact of coronavirus disease (COVID-19): do estrogens play a role?

Grandi G, Facchinetti F, Bitzer J.

Eur J Contracept Reprod Health Care. 2020 Jun;25(3):233-234.

70) Contraception during Coronavirus-Covid 19 pandemia. Recommendations of the Board of the Italian Society of Contraception.

Fruzzetti F, Cagnacci A, Primiero F, De Leo V, Bastianelli C, Bruni V, Caruso S, Di Carlo C, Farris M, **Grandi G**, Grasso A, Guida M, Meriggiola M, Paoletti AM, Cianci A, Nappi C, Volpe A.

Eur J Contracept Reprod Health Care. 2020 Jun;25(3):231-232

71) BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.

Toss A, Molinaro E, Venturelli M, Domati F, Marcheselli L, Piana S, Barbieri E, **Grandi G**, Piombino C, Marchi I, Tenedini E, Tagliafico E, Tazzioli G, Cortesi L.

Cancers (Basel). 2020 May 15;12(5):1252.

72) The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype.

Grandi G, Perrone AM, Toss A, Vitagliano A, Friso S, Facchinetti F, Cortesi L, Cascinu S, De Iaco P.

Minerva Med. 2020 Apr;111(2):133-140.

73) Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.

Grandi G, Caroli M, Alboni C, Cortesi L, Toss A, Barbieri E, Botticelli L, Facchinetti F.

Fam Cancer. 2020 Oct;19(4):291-295. doi: 10.1007/s10689-020-00179-0.

74) Estetrol (E4): the new estrogenic component of combined oral contraceptives.

Grandi G, Del Savio MC, Lopes da Silva-Filho A, Facchinetti F.

Expert Rev Clin Pharmacol. 2020 Apr;13(4):327-330.

75) Surface roughness of different contraceptive vaginal rings: evaluation by scanning electron microscope (SEM).

Grandi G, Timò A, Sammarini M, Del Savio MC, Facchinetti F.

Eur J Contracept Reprod Health Care. 2020 Feb;25(1):60-64.

76) Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age.

Grandi G, Imbrogno MG, Cainazzo MM, Pini LA, Baraldi C, Guerzoni S, Nappi RE, Facchinetti F.

Eur J Obstet Gynecol Reprod Biol. 2019 Nov;242:63-67.

77) A regional audit system for stillbirth: a way to better understand the phenomenon.

Po' G, Monari F, Zanni F, **Grandi G**, Lupi C, Facchinetti F; Stillbirth Emilia-Romagna Audit Group. BMC Pregnancy Childbirth. 2019 Aug 5;19(1):276.

- 78) Combined hormonal contraceptives in BRCA gene mutation carriers: why not?
Grandi G, Sammarini M, Del Savio MC, Toss A, Facchinetti F.
 Eur J Contracept Reprod Health Care. 2019 Dec;24(6):417-419
- 79) Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
Grandi G, Perrone AM, Chiossi G, Friso S, Toss A, Sammarini M, Facchinetti F, Botticelli L, Palma F, De Iaco P.
 Gynecol Oncol. 2019 Jul;154(1):163-168.
- 80) Hereditary ovarian cancers: state of the art.
 Toss A, Molinaro E, Sammarini M, Del Savio MC, Cortesi L, Facchinetti F, **Grandi G**.
 Minerva Med. 2019 Aug;110(4):301-319.
- 81) Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis.
 Barra F, Romano A, **Grandi G**, Facchinetti F, Ferrero S.
 Expert Opin Investig Drugs. 2019 Jun;28(6):501-504.
- 82) Estradiol in non-oral hormonal contraception: a "long and winding road".
Grandi G, Barra F, Ferrero S, Facchinetti F.
 Expert Rev Endocrinol Metab. 2019 May;14(3):153-155.
- 83) A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.
 Barra F, **Grandi G**, Tantari M, Scala C, Facchinetti F, Ferrero S.
 Expert Opin Biol Ther. 2019 Apr;19(4):343-360.
- 84) Hormonal contraception in women with endometriosis: a systematic review.
Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F.
 Eur J Contracept Reprod Health Care. 2019 Feb;24(1):61-70.
- 85) Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.
 Facchinetti F, Orrù B, **Grandi G**, Unfer V.
 Gynecol Endocrinol. 2019 Mar;35(3):198-206.
- 86) Levonorgestrel-releasing intra-uterine systems as female contraceptives.
Grandi G, Farulla A, Sileo FG, Facchinetti F.
 Expert Opin Pharmacother. 2018 May;19(7):677-686.
- 87) The Jellyfish Sign: A New Sonographic Cervical Marker to Predict Maternal Morbidity in Abnormally Invasive Placenta Previa.
 Bertucci E, Sileo FG, **Grandi G**, Fenu V, Cani C, Mancini L, Mataka E, Facchinetti F.
 Ultraschall Med. 2019 Feb;40(1):40-46.
- 88) Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History.
Grandi G, Toss A, Cagnacci A, Marcheselli L, Pavesi S, Facchinetti F, Cascinu S, Cortesi L.
 Clin Breast Cancer. 2018 Feb;18(1):e15-e24.
- 89) Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle?
Grandi G, Facchinetti F, Bitzer J.
 Eur J Contracept Reprod Health Care. 2017 Aug;22(4):245-246
- 90) Narrow implants (2.75 and 3.25 mm diameter) supporting a fixed splinted prostheses in posterior regions of mandible: one-year results from a prospective cohort study.
 Grandi T, Svezia L, **Grandi G**.
 Int J Implant Dent. 2017 Sep 8;3(1):43.
- 91) Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.

Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, Xholli A, **Grandi G**, Cagnacci A, Federico M.

Oncology. 2017;93(6):377-386.

92) ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives.

Merki-Feld GS, Apter D, Bartfai G, **Grandi G**, Haldre K, Lech M, Lertxundi R, Lete I, Lobo Abascal P, Raine S, Roumen F, Serfaty D, Shulman LP, Skouby S, Bitzer J.

Eur J Contracept Reprod Health Care. 2017 Aug;22(4):247-249.

93) A comparison of two implants with conical vs internal hex connections: 1-year post-loading results from a multicentre, randomised controlled trial.

Cannata M, Grandi T, Samarani R, Svezia L, **Grandi G**.

Eur J Oral Implantol. 2017;10(2):161-168.

94) The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis.

Grandi G, Mueller MD, Bersinger NA, Facchinetti F, McKinnon BD.

Gynecol Endocrinol. 2017 Sep;33(9):712-715.

95) PET/CT guided surgical excision of small abdominal wall metastases in morbidly obese endometrial cancer patients.

Papadia A, Nirgianakis K, Gasparri ML, **Grandi G**, Bolla D, Klaeser B, Mueller MD.

Minerva Ginecol. 2017 Apr;69(2):206-207.

96) The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation.

Toss A, **Grandi G**, Cagnacci A, Marcheselli L, Pavesi S, De Matteis E, Razzaboni E, Tomasello C, Cascinu S, Cortesi L.

Oncotarget. 2017 Feb 7;8(6):9144-9154.

97) TNF α -induced IKK β complex activation influences epithelial, but not stromal cell survival in endometriosis.

Kocbek V, **Grandi G**, Blank F, Wotzkow C, Bersinger NA, Mueller MD, Kyo S, McKinnon BD.

Mol Hum Reprod. 2016 Nov;22(11):768-777.

98) Vaginal alpha-lipoic acid shows an anti-inflammatory effect on the cervix, preventing its shortening after primary tocolysis. A pilot, randomized, placebo-controlled study.

Grandi G, Pignatti L, Ferrari F, Dante G, Neri I, Facchinetti F.

J Matern Fetal Neonatal Med. 2017 Sep;30(18):2243-2249.

99) Association between urinary incontinence and climacteric symptoms in postmenopausal women.

Cagnacci A, Palma F, Carbone MM, **Grandi G**, Xholli A.

Menopause. 2017 Jan;24(1):77-84.

100) Laparoscopic management of ectopic pregnancies: a comparison between interstitial and "more distal" tubal pregnancies.

Nirgianakis K, Papadia A, **Grandi G**, McKinnon B, Bolla D, Mueller MD.

Arch Gynecol Obstet. 2017 Jan;295(1):95-101.

101) Progestin suppressed inflammation and cell viability of tumor necrosis factor- α -stimulated endometriotic stromal cells.

Grandi G, Mueller M, Bersinger N, Papadia A, Nirgianakis K, Cagnacci A, McKinnon B.

Am J Reprod Immunol. 2016 Oct;76(4):292-8.

102) Dienogest mediates midkine suppression in endometriosis.

Nirgianakis K, **Grandi G**, McKinnon B, Bersinger N, Cagnacci A, Mueller M.

Hum Reprod. 2016 Sep;31(9):1981-6.

103) Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis.

Grandi G, Mueller MD, Papadia A, Kocbek V, Bersinger NA, Petraglia F, Cagnacci A, McKinnon B.

J Reprod Immunol. 2016 Sep;117:30-8.

104) Metabolic impact of combined hormonal contraceptives containing estradiol.

Grandi G, Napolitano A, Cagnacci A.

Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):779-87.

105) Impact of laparoscopic cystectomy of endometriotic and non-endometriotic cysts on ovarian volume, antral follicle count (AFC) and ovarian doppler velocimetry.

Cagnacci A, Bellafronte M, Xholli A, Palma F, Carbone MM, Di Carlo C, **Grandi G**.

Gynecol Endocrinol. 2016;32(4):298-301.

106) Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.

Gasparri ML, **Grandi G**, Bolla D, Gloor B, Imboden S, Panici PB, Mueller MD, Papadia A.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1509-20.

107) Does dienogest influence the inflammatory response of endometriotic cells? A systematic review.

Grandi G, Mueller M, Bersinger NA, Cagnacci A, Volpe A, McKinnon B.

Inflamm Res. 2016 Mar;65(3):183-92.

108) The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life.

Grandi G, Toss A, Cortesi L, Botticelli L, Volpe A, Cagnacci A.

Biomed Res Int. 2015;2015:751571.

109) Body composition and resting metabolic rate of perimenopausal women using continuous progestogen contraception.

Napolitano A, Zanin R, Palma F, Romani C, **Grandi G**, Di Carlo C, Cagnacci A.

Eur J Contracept Reprod Health Care. 2016;21(2):168-75.

110) Effect of oral contraceptives containing estradiol and norgestrel acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea.

Grandi G, Napolitano A, Xholli A, Tirelli A, Di Carlo C, Cagnacci A.

Gynecol Endocrinol. 2015 Oct;31(10):774-8.

111) Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Toss A, Tomasello C, Razzaboni E, Contu G, **Grandi G**, Cagnacci A, Schilder RJ, Cortesi L.

Biomed Res Int. 2015;2015:341723.

112) Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.

Grandi G, Xholli A, Napolitano A, Palma F, Cagnacci A.

Reprod Sci. 2015 May;22(5):626-32.

113) Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol.

Grandi G, Xholli A, Napolitano A, Piacenti I, Bellafronte M, Cagnacci A.

Contraception. 2014 Nov;90(5):529-34.

114) Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol.

Grandi G, Piacenti I, Volpe A, Cagnacci A.

Gynecol Endocrinol. 2014 Sep;30(9):676-80.

115) Intensity of menstrual pain and estimated angle of uterine flexion.

Cagnacci A, **Grandi G**, Cannoletta M, Xholli A, Piacenti I, Volpe A.

Acta Obstet Gynecol Scand. 2014 Jan;93(1):58-63.

116) Pharmacokinetic evaluation of desogestrel as a female contraceptive.

Grandi G, Cagnacci A, Volpe A.

Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):1-10.

117) Intermenstrual pelvic pain, quality of life and mood.

Grandi G, Xholli A, Ferrari S, Cannoletta M, Volpe A, Cagnacci A.

Gynecol Obstet Invest. 2013;75(2):97-100. doi: 10.1159/000343997.

118) Clinical outcome and bone healing of implants placed with high insertion torque: 12-month results from a multicenter controlled cohort study.

Grandi T, Guazzi P, Samarani R, **Grandi G**.

Int J Oral Maxillofac Surg. 2013 Apr;42(4):516-20. doi: 10.1016/j.ijom.2012.10.013. Epub 2012 Nov 16.

119) Immediate loading of four (all-on-4) post-extractive implants supporting mandibular cross-arch fixed prostheses: 18-month follow-up from a multicentre prospective cohort study.

Grandi T, Guazzi P, Samarani R, **Grandi G**.

Eur J Oral Implantol. 2012 Autumn;5(3):277-85.

120) Prevalence of menstrual pain in young women: what is dysmenorrhea?

Grandi G, Ferrari S, Xholli A, Cannoletta M, Palma F, Romani C, Volpe A, Cagnacci A.

J Pain Res. 2012;5:169-74. doi: 10.2147/JPR.S30602.

212) Immediate loading of two unsplinted implants retaining the existing complete mandibular denture in elderly edentulous patients: 1-year results from a multicentre prospective cohort study.

Grandi T, Guazzi P, Samarani R, Garuti G, **Grandi G**.

Eur J Oral Implantol. 2012 Spring;5(1):61-8.

Modena (Italy) 17/06/2026

Prof. Dr. Giovanni Grandi

